---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000058"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-08-04T21:20:45+00:00"
generated_at: "2026-08-04T21:22:14.269728+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cumberland closes $100M Apotex deal, pays $1.50 special dividend, reports Q2 loss

## Summary
- Closed $100M strategic transaction with Apotex Health; received $111M total including inventory and transition services.
- Paid special cash dividend of $1.50 per share on July 31, 2026 to shareholders of record July 23.
- Q2 2026 loss from continuing operations $3.1M; net loss $4.1M; cash $4M; retired $5.2M credit line.
- Phase 2 ifetroban in DMD showed biomarker evidence of cardiac protection; cancer metastasis study met safety endpoint.
- Metastatic recurrence 17% ifetroban vs 50% placebo (p=0.09); deaths from metastasis 0% vs 30% (p=0.037).

## SEC filing metadata
- accession: 0001087294-26-000058
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-08-04T21:20:45+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/0001087294-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/cpix-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000058
- JSON: https://secwatch.observer/filing/0001087294-26-000058.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.